Zepatier is an oral, fixed combination of two antiviral agents, elbasvir and grazoprevir, that is used to treat chronic hepatitis C, genotypes 1 and 4. This antiviral combination has been associated with low rate of transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent idiosyncratic liver injury with jaundice. However, like all effective direct acting antiviral agents for hepatitis C, Zepatier is considered capable of causing reactivation of hepatitis B in susceptible patients and transient hepatic decompensation in patients with cirrhosis.